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Abstract Ayoung female with recurrent tophaceous gout and
infertility presented to our clinic. On clinical evaluation,
hypoglycaemia, hypertriglyceridaemia, lactic acidosis, and
hepatomegaly were noted. Targeted gene sequencing revealed
a novel composite heterozygous c.190G>T/c.508C>T muta-
tion in the G6PC gene of the patient, leading to a diagnosis of
glycogen storage disease type Ia. Her father possessed a het-
erozygous c.190G>T mutation, and her mother possessed a
heterozygous c.508C>T mutation. A search of the previous
literature revealed 16 reported cases of glycogen storage dis-
ease type Ia with gout. Here, we describe a female patient with
gout, review previous cases, and discuss the mechanisms of
gout and hyperuricaemia in glycogen storage disease type Ia.
Keywords Glycogen storage disease type Ia . Gout .
Hyperuricaemia
Introduction
Gout is a common chronic crystal arthritis predominantly
found in elderly males. Gout in females, however, is less com-
mon, especially in premenopausal women; according to the
UK database, the incidence of female gout with an onset age
younger than 20 years is 1/10,000 [1]. In young female gout
patients, genetic causes should be carefully evaluated.
Glycogen storage diseases are a group of inherited disorders
characterized by impaired glycogen utilization in the liver or
muscle. Gout and hyperuricaemia are common presentations
[2]. Here, we report the atypical case of a female premeno-
pausal patient with a diagnosis of gout who possessed a novel
composite heterozygous mutation of the G6PC gene, leading
to a diagnosis of glycogen storage disease type Ia (GSD-Ia).
We then reviewed the previous reports of GSD-Ia with docu-
mentation of gout.
Case report
A 27-year-old female presented to the Gout Clinic of Peking
Union Medical College Hospital with recurrent arthritis and
infertility. Fourteen years before presentation, she noticed pro-
trusion of her right ankle but did not undergo evaluation at a
hospital. Eight years before presentation, at age 19, she expe-
rienced acute pain and swelling of her right ankle. The pain
resolved spontaneously but recurred 6 to 7 times/year, involv-
ing the bilateral metatarsophalangeal (MTP) joints, bilateral
ankles, and right knee. Her serum urate level (SUA) was ele-
vated to 789 μmol/L. A diagnosis of gout was made, and she
was prescribed NSAIDs for pain relief and allopurinol and
benzbromarone to lower her urate level. However, she
discontinued allopurinol and benzbromarone on her own as
these medications triggered acute flares. Five years before
presentation, she noticed multiple nodules in her MTP joints,
ankles, and fingers. The nodules on her feet interfered with
normal walking. She also complained of the inability to con-
ceive after 3 years of attempts. Her age at menarche was
14 years, and her cycles were irregular. She was reported to
prefer snacks and fatty food during her childhood. Her father
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had hypertension. Her grandfather had an SUA level greater
than 400 μmol/L but without gout. On physical examination,
the patient was generally healthy, with a height of 168 cm and
a weight of 55 kg. Her blood pressure was 120/80 mmHg.
Cardiac and pulmonary examinations were normal. On ab-
dominal palpation, the liver was enlarged with a normal soft
texture. A joint examination revealed multiple nodules on the
bilateral MTP1 joints, ankles, and fingers.
A serological examination after overnight fasting revealed
a SUA level of 548 μmol/L, serum creatinine (Cr) level of
49 μmol/L, fasting glucose level of 3.6 mmol/L, total triglyc-
eride level of 6.22 mmol/L, and total cholesterol level of
6.60 mmol/L. Her resting lactate level was 7.4 mmol/L. Her
24-h urine urate level was 2.262 mmol/24 h, and her fractional
excretion of uric acid (FE-UA) was 2.48%. Her liver enzymes
were normal. The estrogen level and basal body temperature
curve were normal for her age and menstrual status. Renal
ultrasonography revealed normal kidney size with possible
calcium deposits in the bilateral renal medulla. Computed to-
mography (CT) imaging of her abdomen showed hepatomeg-
aly without nodules. The pelvic ultrasonography and
salpingography findings were normal. Serum examinations
of her parents and her husband were normal.
Whole bloodDNAwas extracted from all four familymem-
bers (the patient, both parents, and her husband) after signing
an informed consent form. A genetic study was first conducted
with a target gene sequencing approach. A search of the
OMIM, NIH, and PubMed databases using the key words
BFEMALE,^ BGOUT,^ and BHYPERLACTACIDEMIA^
indicated familial juvenile hyperuricaemic nephropathy, glyco-
gen storage disease type I, and glycogen storage disease type
II. Next-generation sequencing was used to sequence each of
the exons of the UMOD, RENIN, G6PC, SLC37A4, and GAA
genes, as well as two SNP loci (rs2231142 and rs72552713) of
ABCG2 found in our previous report of a family including a
female with gout.
The genetic sequencing results showed that UMOD,
RENIN, SLC37A4, GAA and rs72552713 of ABCG2 were all
normal in the patient and her family. Sequencing of the G6PC
gene revealed composite heterozygous c.190G>T/c.508C>T
mutations in the patient, a heterozygous c.190G>T mutation
in her father, and a heterozygous c.508C>T mutation in her
mother. The genetic analysis of her husband was normal. The
c.190G>T mutation was located on exon 1 and encoded a
missense mutation of p.V64L, whereas the c.508C>T muta-
tion was located on exon 4 and encoded a nonsense mutation
of p.R170X (Fig. 1). Sequencing of 50 healthy females and
100 healthy males at the two loci produced normal results. To
our knowledge, the c.190G>T mutation has not been reported
in previous literature.
Literature review
We then searched PubMed using the keywords BGLYCOGEN
STORAGEDISEASE TYPE IA^ and BGOUT^ and restricted
the language to English. Patients with biopsy and/or gene
sequencing confirmed GSD-Ia, as well as those with docu-
mented gouty arthritis, were reviewed, whereas those with
Fig. 1 Protein structures of G6C and the mutations found in this study.
The G6PC protein contains nine trans-membrane domains and ten
topological domains. There are two binding sites on residue 83 and 170
(yellow arrowhead) and two active sites on residues 119 and 176 (red
arrowhead). The two mutations, shown by the black arrows, were
c.190G>T, resulting in p.V64L and c.508C>T, encoding p.R170X. The
gray arrowheads indicate previous mutations reported in GSD1a patients
complicated with gout
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other types of glycogen storage diseases and hyperuricaemia
without gout flares were excluded. A total of 16 cases were
available for review (Table 1). Among these cases, the male-
to-female ratio was 9:7. Gout developed after puberty and was
usually severe. Patient 1 had catastrophic axial gout resulting
in irreversible paralysis. In contrast, the clinical presentations
of glycogen storage were relatively mild, and ten (62.5 %)
patients were not diagnosed until the gout was evaluated. All
pat ien ts had hepatomegaly, and most exhib i ted
hypoglycaemia, hypertriglyceridaemia, and lactate acidosis.
Nine patients had recorded short stature, and four patients
had recorded delayed puberty. Patient 4 experienced recorded
irregular menses and a spontaneous abortion. Most of the
patients were diagnosed by liver biopsy at a relatively late
age (average age, 20.5±3.06 years). G-6Pase enzyme activity
was analyzed in five patients (patients 3, 4, 6, 8, and 11),
which revealed partial or complete loss of enzyme activity.
An additional four patients (patients 6, 7, 9, and 10) had un-
dergone gene sequencing, two of which (patients 6 and 7)
possessed a composite heterozygous p.R83C/p.M5R muta-
tion, whereas the other two patients (patients 9 and 10) pos-
sessed a homozygous p.M121V mutation (Table 1).
Discussion
This case of a female gout patient was unusual in several
ways. The age of gout onset was early, and the disease course
was severe, with formation of multiple large stones only
3 years after the first gout flare. She also exhibited
hypoglycaemia, hypertriglyceridaemia, lactic acidosis, and
hepatomegaly, indicating a metabolic abnormality. Irregular
menses and infertility also raised suspicion. A genetic study
revealed a novel composite heterozygous mutation of the
G6PC gene. Given the typical clinical presentation and the
presence of a composite heterozygous missense mutation, a
diagnosis of GSD-Ia was made.
Gout and hyperuricaemia are common phenotypes ob-
served in several inherited diseases [15]. GSD-Ia (OMIM:
232220), also known as Von Gierke disease, is a well-
known autosomal recessive disease characterized by the in-
ability to convert stored hepatic glycogen into circulating glu-
cose [2]. Patients are usually diagnosed as babies, with a char-
acteristic doll face, protruding abdomen and hepatomegaly,
hypoglycaemic attacks, hypertriglyceridaemia, lactic acidosis,
and growth and mental retardation. Patients usually fail to
thrive if they are not properly treated [2].
Hyperuricaemia is also a feature, whereas gout is found
only in those who reach puberty. Alepa et al. [11] reported
decreased renal uric acid secretion in GSD-Ia patients
(341∼381 mg/24 h; normal range 426 ± 81 mg/24 h).
However, the finding that the uricosuric agent probenecid is
ineffective to lower uric acid, whereas the xanthine oxidase
inhibitor allopurinol can effectively maintain a normal SUA
level, indicates that over-production might be the main mech-
anism of hyperuricaemia in GSD-Ia patients [12]. Jakovcic
and Sorensen [12] used radioactive glycine-C14 to study the
process of glycogen conversion in GSD-Ia patients. They
found that the uric acid pool and daily production in GSD-Ia
patients were 63 and 25 mg/kg, respectively, which are signif-
icantly higher than the normal values of 20 and 10 mg/kg,
respectively; in contrast, the recovery of uric acid-C14 from
the urine was 31.5 % of the injected dose, which was lower
than the normal value of >65 %. Thus, in GSD-Ia patients,
both over-production and under-secretion contributes to
hyperuricaemia.
The culprit gene of GSD-Ia is G6PC, which encodes
glucose-6-phophatase (G6Pase). Normally, G6Pase converts
glucose-6-phosphate into glucose and inorganic phosphate
(Pi), which is an important step to maintain normal blood
glucose levels during glycolysis and gluconeogenesis.
However, in the absence of G6Pase, glucose-6-phosphate ac-
cumulates in the cells and is then redirected into the pentose
phosphate pathway, producing ribose-5-phosphate [12]. In the
liver, ribose-5-phosphate degrades into phosphoribosyl pyro-
phosphate (PRPP), which is the first step in the uric acid de
novo synthesis pathway [16]. In addition, the inability of
glucose-6-phosphate to release Pi impairs the ATP compensa-
tion processes, resulting in an accumulation of the ATP deg-
radation products ADP and AMP. ADP and AMP are then
deaminated into IMP and enter the uric acid salvage synthesis
pathway [17]. Thus, in GSD-Ia, both the de novo and salvage
synthesis pathways of uric acid are accelerated. In addition,
serum lactate has been shown to trans-stimulate the urate re-
absorption transporters, urate transporter 1 (URAT1), and glu-
cose transporter 9 (GLUT9) [18, 19], in the renal proximal
tubules, resulting in increased uric acid reabsorption and de-
creased uric acid secretion.
The patient in this case and in four other cases reported
irregular menses. In one study of 13 patients with GSD-Ia
(mean age 11.2 years), all patients older than 4.8 years of
age had a polycystic ovarian appearance and significantly
higher basal and 2-h plasma insulin levels than the control
subjects. The serum gonadotropin, androgen, IGF-I and sex
hormone binding globulin (SHBG) levels were mostly normal
[20]. In another study of 25 women with GSD-Ia, 8/25 (32 %)
patients had delayed menarche (defined as ≥15 years of age),
12/25 (48 %) had irregular cycles, and 6/18 (33.3 %) had
documented polycystic ovaries. In five patients with GSD-
Ia, five successful spontaneous pregnancies and one aided
pregnancy were reported [21]. The mechanisms of these ab-
normalities were unclear. Sechi et al. [21] found an association
between age at GSD-Ia diagnosis and age at menarche
(p=0.0068) and between age at starting a corn starch-based
diet and age at menarche (p=0.01). They concluded that an
early diagnosis with early implementation of a corn starch-
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based diet might prevent delayed puberty. The patient in this
case had a normal ovarian appearance and female hormone
levels but irregular cycles and infertility, which might be more
complicated, involving other medical conditions, hormonal
changes, and psychological and social factors.
G6PC contains five exons encompassing 12.5 kb on chromo-
some 17q21. At present, over 100mutations have been reported.
However, only a limited number of mutations account for the
majority of GSD-Ia cases, among which, c.648G>T (p.L216L),
a splicing mutation, and c.248G>A (p.R83H), a missense muta-
tion, are the most prevalent mutations in the Chinese, Japanese,
and Korean populations [22, 23], whereas c.247C>T (p.R83C)
and c.1039C>T (p.Q347X) are the most prevalent mutations
among Caucasians [23]. The G6Pase protein is a nine-trans-
membrane protein with two binding sites (loci 83 and 170) and
two active sites (loci 119 and 176) [22]. In the present case,
c.190G>T encoded a missense mutation, p.V64L, in trans-
membrane helix-2, whereas c.508C>T encoded a nonsense mu-
tation of p.R170X in the second binding site (Fig. 1). The trans-
membrane helices are crucial for correct folding, and abnormal
proteins are designated for degradation [24]. The p.W63R/
p.G68R mutation in helix-2 was shown to result in reduced
levels of the G6Pase protein [24], whereas the p.M121V muta-
tion in helix-3, found in patients 9 and 10, resulted in 7.8 % of
normal activity during an in vitro expression study [9]. The
binding sites (loci 83 and loci 170) and active sites (loci 119
and 176) compose the catalytic center, and mutations at these
sites, namely p.R83C, p.R83H, p.H119L, p.R170Q, and
p.H176A, completely abolish G6Pase enzymatic activity [24].
Carves et al. [7] reported a youngmale patient with no enzymatic
activity in a liver biopsy specimen who was found to possess a
heterozygous p.R83C/p.M5V mutation. Thus, although we did
not test enzymatic function, the p.V64L/p.170X mutation could
be assumed to impair normal protein function.
Of the five cases reviewed herewith tested enzymatic activity,
the patient (patient 11) with partial enzymatic function deficiency
(2.40 ± 1.98 μmol Pi min−1 g−1, normal 4.7 ± 1.9 μmol
Pi min−1 g−1) had a relatively mild manifestation of GSD-Ia,
whereas the remaining four patients (patients 3, 4, 6, and 8) with
complete enzymatic function deficiency presentedwith early and
typical manifestations of GSD-Ia. Thus, the clinicallymildGSD-
Ia phenotype in the present case might be related to a partial
enzymatic deficiency. However, one GSD-Ia patient with a ho-
mozygous p.P257L mutation, which revealed only 1.2 % of
normal activity during an in vitro expression study, had a mild
phenotype [25], whereas another patient with a composite het-
erozygous p.E110Q/p.G222R mutation, which retained 17 and
4 % of normal activity, respectively, manifested typical severe
symptoms [26]. Variable phenotypes with the same G6PC
genotype have been reported [27]. Thus, a genotype-
phenotype correlation is lacking, and other modifying fac-
tors and/or genes might be present that affect the pheno-
type of GSD-Ia patients.
Frequent ingestion of uncooked corn starch is the main
treatment for GSD-Ia and might improve growth and reduce
mortality [28]. Potassium citrate is preferred to correct lactic
acidosis [29]. Allopurinol, a xanthine oxidase inhibitor that
blocks uric acid production, can effectively lower the SUA
level, whereas uricosuric agents were not effective [12].
Liver transplantation was reported in one patient with gout
(Patient 8). However, that patient’s SUA level increased from
484 to 711 μmol/L after transplantation, and he suffered from
gout flares even after other serological parameters returned to
normal [8]. Few reports exist on the treatment of GSD-Ia-
related menstruation abnormalities, but early dietary interven-
tion might be associated with correction of menstruation [21].
The patient in this report was advised to ingest complex car-
bohydrates as her main diet and to have frequent snacks be-
tween meals. She was also administered allopurinol with low-
dose colchicine for gout flare prophylaxis. The tophi on her
feet were removed surgically to enable normal walking. At the
time of completion of this manuscript, her SUA level was
360 μmol/L, and she was preparing for in vitro fertilization.
In conclusion, here, we report the case of one female pre-
menopausal gout patient with multiple metabolic abnormalities
and infertility, who was finally diagnosed with GSD-Ia caused
by a novel composite heterozygous mutation, c.190G>T/
c.508C>T, encoding a missense mutation (p.V64V) in one
trans-membrane helix and a nonsense mutation (p.R170X) in
a binding site. Glycogen storage disease should be considered
in young female patients with gout and hyperuricemia.
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